Benign Prostatic Hyperplasia BPH: Tamsulosin and Hypotension

MedicalResearch.com Interview with:
Mahyar Etminan
Assistant Professor University of British Columbia
Therapeutic Evaluation Unit, Provincial Health Services Authority
University of British Columbia, Vancouver

MedicalResearch.com: What are the main findings of the study?

Answer: Tamsulosin resulted in a roughly doubled risk for hypotension needing hospital admission during the first eight weeks after tamsulosin initiation and first eight weeks after restarting tamsulosin treatment.
MedicalResearch.com: What should clinicians and patients take away from your report?

Answer: Physicians should focus on improving counseling strategies to warn patients regarding the first dose phenomenon. Optimal drug adherence should be promoted, given these drugs increase risk for hypotension immediately after gaps in drug therapy.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Answer: Future work is needed to determine whether genetic characteristics or other non-measured risk factors may modify susceptibility to hypotension with tamsulosin.

Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology.

Citation:

Bird ST ,Delaney JAC ,Brophy JM ,Etminan M ,Skeldon SC ,Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ 2013;347:f6320